<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742859</url>
  </required_header>
  <id_info>
    <org_study_id>08-015</org_study_id>
    <nct_id>NCT00742859</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin</brief_title>
  <acronym>EXPLORE-Xa</acronym>
  <official_title>A Phase 2, Randomized, Parallel Group, Dose-Finding, Multicenter, Multinational Study of the Safety, Tolerability and Pilot Efficacy of Three Blinded Doses of the Oral Factor Xa Inhibitor Betrixaban Compared With Open-Label Dose-Adjusted Warfarin in Patients With Non-Valvular Atrial Fibrillation (EXPLORE Xa)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portola Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Portola Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevention of stroke in patients with atrial fibrillation (AF). Hypothesis: In patients with
      non-valvular AF, orally administered betrixaban will provide similar or better efficacy and
      safety than warfarin and it will offer the advantage of not requiring dose adjustments due to
      international normalized ratios (INRs) outside the target range of 2.0 to 3.0 and a more
      consistent level of anticoagulation over time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and tolerability of betrixaban at doses of 40 mg, 60 mg and 80 mg given
      orally once a day for at least 3 months compared to dose-adjusted warfarin in patients with
      non-valvular atrial fibrillation (AF).

      This is a Phase 2, exploratory, randomized, parallel group, multicenter, active comparator,
      dose finding study of patients with documented non-valvular AF. Patients will be randomized
      (1:1:1:1) to 1 of 4 treatment groups (approximately 125 patients per group) using an
      interactive voice response system (IVRS). A dynamic randomization will be used to balance
      patients by country, concurrent aspirin use (yes or no) and antecedent warfarin (yes or no).
      The study will be open label for randomization to warfarin versus betrixaban, but the three
      daily doses of betrixaban, 40 mg, 60 mg or 80 mg, will be double-blind (identical capsules
      for all three dose levels). The warfarin-treated patients will be managed according to each
      center's usual clinical routine with INR monitoring and dose-adjustments in order to maintain
      a target INR of 2.0 to 3.0 at maximum intervals of four weeks. No loading doses or dose
      titrations will be used for betrixaban. The betrixaban dose should be ingested in the evening
      (e.g. at bedtime), preferably at least 2 hours after the evening meal. Note: acenocumerol may
      be substituted for warfarin as indicated by local practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure-adjusted Incidence Rate of Major or Clinically Relevant Non-major Bleeding Episode</measure>
    <time_frame>A maximum of 1 year</time_frame>
    <description>The primary endpoint is the time to the first occurrence of major or clinically relevant non-major bleeding. This was presented as the exposure adjusted incidence rate which was calculated as number of subjects experiencing the event divided by total person years across all subjects, where if a patient experiencing the event, year was from first dose date to the first occurrence of the event, and to last study date if not. The confidence interval was calculated via the exact Poisson distribution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exposure-adjusted Incidence Rate of Any Bleeding (Major, Clinically Relevant Non-major, or Minimal)</measure>
    <time_frame>A maximum of 1 year</time_frame>
    <description>The time to the first occurrence of any bleeding event. This was presented as the exposure adjusted incidence rate which was calculated as number of subjects experiencing the event divided by total person years across all subjects, where if a patient experiencing the event, year was from first dose date to the first occurrence of the event, and to last study date if not. The confidence interval was calculated via the exact Poisson distribution.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">508</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Arm 1: Betrixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betrixaban, 40 mg, orally, once daily for at least 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Betrixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betrixaban, 60 mg, orally, once daily for at least 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Betrixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betrixaban, 80 mg, orally, once daily for at least 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin will be prescribed by investigators according to the standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>betrixaban</intervention_name>
    <description>orally, once daily for at least 3 months</description>
    <arm_group_label>Arm 1: Betrixaban</arm_group_label>
    <arm_group_label>Arm 2: Betrixaban</arm_group_label>
    <arm_group_label>Arm 3: Betrixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin will be prescribed by the investigator according to the standard of care.</description>
    <arm_group_label>Arm 4: Warfarin</arm_group_label>
    <other_name>Coumadin</other_name>
    <other_name>Acenocoumarol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age ≥18 years.

          -  If the patient is a woman, she must be without reproductive potential (i.e.,
             postmenopausal for ≥2 years or after hysterectomy).

          -  AF at the time of enrollment (randomization) or documented within the last year by
             Holter, ECG, rhythm strip, pacemaker or other intracardiac recording, resulting in an
             indication for anticoagulation with warfarin, acenocumerol, phenprocoumon, or other
             Vitamin K antagonist in the opinion of the treating physician.

          -  One or more of the following risk factor(s) for stroke:

               1. Age 75 years or older.

               2. Prior stroke, TIA or systemic (i.e., central nervous system) embolus at least 30
                  days remote from the time of screening.

               3. Symptomatic congestive heart failure within 3 months echocardiography,
                  radionuclide study or contrast angiography.

               4. Hypertension requiring pharmacological treatment.

               5. Diabetes.

               6. Age of 55 years or older and previous coronary artery disease or known peripheral
                  artery disease.

        Exclusion Criteria:

          -  Body weight less than 40 kg (88 lbs).

          -  Need for either hemodialysis or peritoneal dialysis (or likely to require it within
             one year).

          -  AF due to reversible causes (e.g., thyrotoxicosis, pericarditis, cardiac surgery,
             pulmonary embolism).

          -  Mechanical prosthetic valve (bioprosthetic valve is allowed) or valvular disease
             likely to be operated on within one year.

          -  History (including family history) or symptoms of a congenital or acquired bleeding
             disorder or vascular malformation; or a history of intracranial, retroperitoneal, or
             intraocular bleeding within the last 6 months; or is felt to be at high risk for
             bleeding for other reasons including from significant liver disease. This also
             includes gastrointestinal bleeding within 90 days before randomization or
             endoscopically verified ulcer disease within 30 days of screening.

          -  Conditions other than AF that require chronic anticoagulation (e.g. prosthetic
             mechanical heart valve).

          -  Persistent, uncontrolled hypertension (SBP &gt;160 mm Hg on repeated measurements).

          -  Active infective endocarditis.

          -  Scheduled major surgery.

          -  Planned pulmonary vein ablation or surgical procedure for cure of AF or flutter.

          -  Recent ischemic stroke, systemic embolic event or acute coronary syndrome within 30
             days.

          -  Severe co-morbid condition with life expectancy of ≤1 year.

          -  Previous known history of genetic coagulopathy (e.g., Factor V Leiden, Protein C
             Deficiency, Protein S Deficiency, Antiphospholipid Syndrome, etc.).

          -  Evidence at Screening of:

               1. Platelet count &lt;100,000/mm3.

               2. Serum alanine aminotransferase (ALT) or aspirate aminotransferase (AST) &gt;2 times
                  upper limit of normal (ULN).

               3. A history (including family history) of &quot;Long QT Syndrome&quot;.

          -  Aspirin &gt;162 mg daily.

          -  Use of verapamil (pending the availability of a drug interaction study with
             betrixaban).

          -  Active alcohol or drug abuse, or psychosocial reasons that make study participation
             impractical.

          -  Use of an investigational drug or device within the past 30 days.

          -  Inability to comply with INR monitoring or other protocol-related activities.

          -  Unable to give written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Connolly, MD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Population Health Research Institute, McMaster University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Diaz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Cardiovascular de Rosario, Argentina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Dorian, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Toronto, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Ezekowitz, MD, PhD,</last_name>
    <role>Study Director</role>
    <affiliation>Lankenau Institute for Medical Research and The Heart Center, United States</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan H. Hohnloser, MD</last_name>
    <role>Study Director</role>
    <affiliation>Johann Wolgang Goethe University, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Hillsboro</city>
        <state>Oregon</state>
        <zip>97123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Longueuil</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portola Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2008</study_first_posted>
  <results_first_submitted>July 20, 2017</results_first_submitted>
  <results_first_submitted_qc>August 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 26, 2017</results_first_posted>
  <disposition_first_submitted>November 30, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>November 30, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 2, 2016</disposition_first_posted>
  <last_update_submitted>September 25, 2017</last_update_submitted>
  <last_update_submitted_qc>September 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Betrixaban</keyword>
  <keyword>Factor Xa inhibitor</keyword>
  <keyword>Warfarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betrixaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Acenocoumarol</mesh_term>
    <mesh_term>Factor Xa Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between 31 October 2008 and 05 November 2009, 508 patients were enrolled by 35 study centers in 3 countries (USA, Canada, Germany). Patients were randomized to 1 of 4 treatment groups (1:1:1:1 allocation). The study was open-label for warfarin, while the 3 daily doses of betrixaban (40, 60, or 80 mg) were double-blinded.</recruitment_details>
      <pre_assignment_details>561 patients were screened for study participation. Of these patients, 508 were randomized, all of whom received at least 1 dose of study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Betrixaban 40 mg</title>
          <description>Betrixaban 40 mg once daily for at least 3 months and no longer than approximately 11 months</description>
        </group>
        <group group_id="P2">
          <title>Betrixaban 60 mg</title>
          <description>Betrixaban 60 mg once daily for at least 3 months and no longer than approximately 11 months</description>
        </group>
        <group group_id="P3">
          <title>Betrixaban 80 mg</title>
          <description>Betrixaban 80 mg once daily for at least 3 months and no longer than approximately 11 months</description>
        </group>
        <group group_id="P4">
          <title>Warfarin</title>
          <description>Dose-adjusted warfarin to maintain an INR of 2.0 to 3.0 with INR measured at maximum intervals of 4 weeks. Treatment duration was at least 3 months and no longer than approximately 11 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="127"/>
                <participants group_id="P3" count="127"/>
                <participants group_id="P4" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="116"/>
                <participants group_id="P4" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Endpoint</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Amendment 2 patient off study drug &gt;4wks</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor req visit schedule noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor request patient out of town</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized patients who took at least 1 dose of study medication after randomization.</population>
      <group_list>
        <group group_id="B1">
          <title>Betrixaban 40 mg</title>
          <description>Betrixaban 40 mg once daily for at least 3 months and no longer than approximately 11 months</description>
        </group>
        <group group_id="B2">
          <title>Betrixaban 60 mg</title>
          <description>Betrixaban 60 mg once daily for at least 3 months and no longer than approximately 11 months</description>
        </group>
        <group group_id="B3">
          <title>Betrixaban 80 mg</title>
          <description>Betrixaban 80 mg once daily for at least 3 months and no longer than approximately 11 months</description>
        </group>
        <group group_id="B4">
          <title>Warfarin</title>
          <description>Dose-adjusted warfarin to maintain an INR of 2.0 to 3.0 with INR measured at maximum intervals of 4 weeks. Treatment duration was at least 3 months and no longer than approximately 11 months</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="127"/>
            <count group_id="B3" value="127"/>
            <count group_id="B4" value="127"/>
            <count group_id="B5" value="508"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.3" spread="8.50"/>
                    <measurement group_id="B2" value="73.8" spread="8.35"/>
                    <measurement group_id="B3" value="72.0" spread="7.65"/>
                    <measurement group_id="B4" value="72.7" spread="8.75"/>
                    <measurement group_id="B5" value="73.0" spread="8.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Count of Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B5" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="89"/>
                    <measurement group_id="B5" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exposure-adjusted Incidence Rate of Major or Clinically Relevant Non-major Bleeding Episode</title>
        <description>The primary endpoint is the time to the first occurrence of major or clinically relevant non-major bleeding. This was presented as the exposure adjusted incidence rate which was calculated as number of subjects experiencing the event divided by total person years across all subjects, where if a patient experiencing the event, year was from first dose date to the first occurrence of the event, and to last study date if not. The confidence interval was calculated via the exact Poisson distribution.</description>
        <time_frame>A maximum of 1 year</time_frame>
        <population>All randomized patients who took at least 1 dose of study medication after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Betrixaban 40 mg</title>
            <description>Betrixaban 40 mg once daily for at least 3 months and no longer than approximately 11 months</description>
          </group>
          <group group_id="O2">
            <title>Betrixaban 60 mg</title>
            <description>Betrixaban 60 mg once daily for at least 3 months and no longer than approximately 11 months</description>
          </group>
          <group group_id="O3">
            <title>Betrixaban 80 mg</title>
            <description>Betrixaban 80 mg once daily for at least 3 months and no longer than approximately 11 months</description>
          </group>
          <group group_id="O4">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin to maintain an INR of 2.0 to 3.0 with INR measured at maximum intervals of 4 weeks. Treatment duration was at least 3 months and no longer than approximately 11 months</description>
          </group>
        </group_list>
        <measure>
          <title>Exposure-adjusted Incidence Rate of Major or Clinically Relevant Non-major Bleeding Episode</title>
          <description>The primary endpoint is the time to the first occurrence of major or clinically relevant non-major bleeding. This was presented as the exposure adjusted incidence rate which was calculated as number of subjects experiencing the event divided by total person years across all subjects, where if a patient experiencing the event, year was from first dose date to the first occurrence of the event, and to last study date if not. The confidence interval was calculated via the exact Poisson distribution.</description>
          <population>All randomized patients who took at least 1 dose of study medication after randomization.</population>
          <units>Number of Patients per 100 Patient years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="127"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="0.05" upper_limit="11.3"/>
                    <measurement group_id="O2" value="10.1" lower_limit="3.28" upper_limit="23.6"/>
                    <measurement group_id="O3" value="10.5" lower_limit="3.41" upper_limit="24.5"/>
                    <measurement group_id="O4" value="14.6" lower_limit="5.85" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Betrixaban 40mg compared to Warfarin</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.017</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Betrixaban 60mg compared to Warfarin</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.546</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.711</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.225</ci_lower_limit>
            <ci_upper_limit>2.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Betrixaban 80mg compared to Warfarin</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.712</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.755</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.239</ci_lower_limit>
            <ci_upper_limit>2.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exposure-adjusted Incidence Rate of Any Bleeding (Major, Clinically Relevant Non-major, or Minimal)</title>
        <description>The time to the first occurrence of any bleeding event. This was presented as the exposure adjusted incidence rate which was calculated as number of subjects experiencing the event divided by total person years across all subjects, where if a patient experiencing the event, year was from first dose date to the first occurrence of the event, and to last study date if not. The confidence interval was calculated via the exact Poisson distribution.</description>
        <time_frame>A maximum of 1 year</time_frame>
        <population>All randomized patients who took at least 1 dose of study medication after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Betrixaban 40 mg</title>
            <description>Betrixaban 40 mg once daily for at least 3 months and no longer than approximately 11 months</description>
          </group>
          <group group_id="O2">
            <title>Betrixaban 60 mg</title>
            <description>Betrixaban 60 mg once daily for at least 3 months and no longer than approximately 11 months</description>
          </group>
          <group group_id="O3">
            <title>Betrixaban 80 mg</title>
            <description>Betrixaban 80 mg once daily for at least 3 months and no longer than approximately 11 months</description>
          </group>
          <group group_id="O4">
            <title>Warfarin</title>
            <description>Dose-adjusted warfarin to maintain an INR of 2.0 to 3.0 with INR measured at maximum intervals of 4 weeks. Treatment duration was at least 3 months and no longer than approximately 11 months</description>
          </group>
        </group_list>
        <measure>
          <title>Exposure-adjusted Incidence Rate of Any Bleeding (Major, Clinically Relevant Non-major, or Minimal)</title>
          <description>The time to the first occurrence of any bleeding event. This was presented as the exposure adjusted incidence rate which was calculated as number of subjects experiencing the event divided by total person years across all subjects, where if a patient experiencing the event, year was from first dose date to the first occurrence of the event, and to last study date if not. The confidence interval was calculated via the exact Poisson distribution.</description>
          <population>All randomized patients who took at least 1 dose of study medication after randomization.</population>
          <units>Number of Patients per 100 Patient years</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="127"/>
                <count group_id="O4" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" lower_limit="31.7" upper_limit="76.5"/>
                    <measurement group_id="O2" value="77.9" lower_limit="53.3" upper_limit="110"/>
                    <measurement group_id="O3" value="56.0" lower_limit="35.9" upper_limit="83.4"/>
                    <measurement group_id="O4" value="103" lower_limit="73.6" upper_limit="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Betrixaban 40mg compared to Warfarin</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.508</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.301</ci_lower_limit>
            <ci_upper_limit>0.856</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Betrixaban 60mg compared to Warfarin</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.308</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.767</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.481</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Betrixaban 80mg compared to Warfarin</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.551</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.332</ci_lower_limit>
            <ci_upper_limit>0.914</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Maximum of 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Betrixaban 40 mg</title>
          <description>Betrixaban 40 mg once daily for at least 3 months and no longer than approximately 11 months</description>
        </group>
        <group group_id="E2">
          <title>Betrixaban 60 mg</title>
          <description>Betrixaban 60 mg once daily for at least 3 months and no longer than approximately 11 months</description>
        </group>
        <group group_id="E3">
          <title>Betrixaban 80 mg</title>
          <description>Betrixaban 80 mg once daily for at least 3 months and no longer than approximately 11 months</description>
        </group>
        <group group_id="E4">
          <title>Warfarin</title>
          <description>Dose-adjusted warfarin to maintain an INR of 2.0 to 3.0 with INR measured at maximum intervals of 4 weeks. Treatment duration was at least 3 months and no longer than approximately 11 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate Antidiuretic Hormone Secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Internaional Normalised Ratio Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Fluid Overload</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Ligament Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Cardiac Neoplasm Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Chronic Lymphocytic Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Colon Cancer Recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Renal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Lumbar Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="127"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="127"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Due to multiple studies, centers and countries this may vary.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Development</name_or_title>
      <organization>Portola Pharmaceuticals, Inc.</organization>
      <phone>650-246-7000</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

